Improving alloreactive CTL immunotherapy for malignant gliomas using a simulation model of their interactive dynamics
- 7 September 2007
- journal article
- research article
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 57 (3) , 425-439
Abstract
Glioblastoma (GBM), a highly aggressive (WHO grade IV) primary brain tumor, is refractory to traditional treatments, such as surgery, radiation or chemotherapy. This study aims at aiding in the design of more efficacious GBM therapies. We constructed a mathematical model for glioma and the immune system interactions, that may ensue upon direct intra-tumoral administration of ex vivo activated alloreactive cytotoxic-T-lymphocytes (aCTL). Our model encompasses considerations of the interactive dynamics of aCTL, tumor cells, major histocompatibility complex (MHC) class I and MHC class II molecules, as well as cytokines, such as TGF-β and IFN-γ, which dampen or increase the pro-inflammatory environment, respectively. Computer simulations were used for model verification and for retrieving putative treatment scenarios. The mathematical model successfully retrieved clinical trial results of efficacious aCTL immunotherapy for recurrent anaplastic oligodendroglioma and anaplastic astrocytoma (WHO grade III). It predicted that cellular adoptive immunotherapy failed in GBM because the administered dose was 20-fold lower than required for therapeutic efficacy. Model analysis suggests that GBM may be eradicated by new dose-intensive strategies, e.g., 3 × 108 aCTL every 4 days for small tumor burden, or 2 × 109 aCTL, infused every 5 days for larger tumor burden. Further analysis pinpoints crucial bio-markers relating to tumor growth rate, tumor size, and tumor sensitivity to the immune system, whose estimation enables regimen personalization. We propose that adoptive cellular immunotherapy was prematurely abandoned. It may prove efficacious for GBM, if dose intensity is augmented, as prescribed by the mathematical model. Re-initiation of clinical trials, using calculated individualized regimens for grade III–IV malignant glioma, is suggested.Keywords
This publication has 55 references indexed in Scilit:
- Cellular and Functional Characterization of Immunoresistant Human Glioma Cell Clones Selected With Alloreactive Cytotoxic T Lymphocytes Reveals Their Up-regulated Synthesis of Biologically Active TGF-βJournal of Immunotherapy, 2007
- Cancer Regression in Patients After Transfer of Genetically Engineered LymphocytesScience, 2006
- Objective Clinical Regression of Metastatic Breast Cancer in Disparate Sites after Use of Whole-Cell Vaccine Genetically Modified to Release SargramostimThe Breast Journal, 2006
- The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses1Neuro-Oncology, 2006
- Mixed immunotherapy and chemotherapy of tumors: modeling, applications and biological interpretationsJournal of Theoretical Biology, 2006
- Downregulation of major histocompatibility complex antigens in invading glioma cells: stealth invasion of the brainLaboratory Investigation, 2005
- Vessel maturation effects on tumour growth: validation of a computer model in implanted human ovarian carcinoma spheroidsEuropean Journal of Cancer, 2005
- Mathematical model of antiviral immune response. I. Data analysis, generalized picture construction and parameters evaluation for hepatitis BJournal of Theoretical Biology, 1991
- Reduction of cytotoxicity to normal tissues by new regimens of cell-cycle phase-specific drugsMathematical Biosciences, 1988
- Qualitative dynamics of a network model of regulation of the immune system: A rationale for the IgM to IgG switchJournal of Theoretical Biology, 1982